

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approvals for drug production and registration for Ambroxol Hydrochloride Injection (including 4ml:30mg, 2ml:15mg and 1ml:7.5mg) in 3-in-1 Polypropylene (PP) plastic ampoule packaging as well as Tirofiban Hydrochloride and Sodium Chloride Injection (250ml and 100ml) in glass bottle packaging from the National Drug Administration of China.

Ambroxol Hydrochloride Injection is under previous type 6 chemical drug, and is used in treatment of respiratory diseases and promotes mucus clearance. Tirofiban Hydrochloride and Sodium Chloride Injection is under previous type 6 chemical drug, and is a cardiovascular drug for patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 7 January 2019

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.